Inactive Instrument

Seagen Inc.

SGEN

US81181C1045

Biotechnology & Medical Research

Seagen Inc. Announces Cessation of Todd E. Simpson as Chief Financial Officer

December 14, 2023 at 08:01 am EST

Seagen Inc. announced cessation of Todd E. Simpson as Chief Financial Officer, effective time of the merger.

Latest news about Seagen Inc.

Takeover rumors send Morphosys to high since July 2021	Feb. 05	DP
Seagen Inc.(NasdaqGS:SGEN) dropped from S&P Biotechnology Select Industry Index	Dec. 18	CI
Seagen Inc.(NasdaqGS:SGEN) dropped from S&P TMI Index	Dec. 18	CI
Seagen Inc.(NasdaqGS:SGEN) dropped from S&P Global BMI Index	Dec. 18	CI
Merck, Pfizer, Astellas Get FDA OK For Expanded Use Of Keytruda Plus Padcev	Dec. 15	DJ
Pfizer: dividend increases, stock rebounds	Dec. 15	CF
Euphoria subsides for Triple-Witching Day	Dec. 15
ANALYST RECOMMENDATIONS : Adobe, Blackrock, Roblox, Snap, US Bancorp...	Dec. 15
HBM Holdings Unit Nona Biosciences Signs Licensing Deal with Seagen for Tumor Medication; Shares Fall 5%	Dec. 15	MT
Seagen Inc.(NasdaqGM:SGEN) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Seagen Inc.(NasdaqGS:SGEN) dropped from NASDAQ-100 Index	Dec. 15	CI
Seagen Inc.(NasdaqGS:SGEN) dropped from FTSE All-World Index	Dec. 15	CI
Pfizer, Inc: A cycle for nothing?	Dec. 14
Pfizer Completes $43 Billion Acquisition of Seagen	Dec. 14	MT
Pfizer: Seagen acquisition now complete	Dec. 14	CF
Seagen Inc. Announces Management Changes	Dec. 14	CI
Seagen Inc. Announces Cessation of David R. Epstein as Chief Executive Officer	Dec. 14	CI
Seagen Inc. Announces Cessation of Todd E. Simpson as Chief Financial Officer	Dec. 14	CI
Seagen Inc.(NasdaqGS:SGEN) dropped from NASDAQ Composite Index	Dec. 14	CI
Pfizer Inc. completed the acquisition of Seagen Inc. from Baker/Tisch Investments, L.P, a funds managed by Baker Brothers Investments and others.	Dec. 13	CI
Pfizer shares sink after it resets 2024 COVID expectations	Dec. 13	RE
Sector Update: Tech Stocks Rise Late Afternoon	Dec. 13	MT
Sector Update: Tech Stocks Mixed Wednesday Afternoon	Dec. 13	MT
Global markets live: BAE Systems, Amazon, Take-Two, Shell, Pfizer...	Dec. 13
Pfizer shares slide as 2024 revenue outlook underwhelms	Dec. 13	AN

Seagen Inc. est spécialisé dans le développement et la commercialisation de thérapies à base d'anticorps monoclonaux destinées au traitement du cancer. Le CA par source de revenus se répartit comme suit : - ventes de produits (87%) ; - royalties (8,4%) ; - revenus issus d'accords de collaboration et de licence (4,6%).

Sector

Biotechnology & Medical Research

Calendar

2024-07-24 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research

Seagen Inc.

Equities

SGEN

US81181C1045

Biotechnology & Medical Research

Seagen Inc. Announces Cessation of Todd E. Simpson as Chief Financial Officer

Latest news about Seagen Inc.

Chart Seagen Inc.

Company Profile

Sector Other Biotechnology & Medical Research